Elizabeth Yeu-Lin compensation by year
Tarsus Pharmaceuticals Summary Compensation Table · the one fiscal year held| Component | FY2024 |
|---|---|
| Salary | $78,182 |
| Bonus | $25,000 |
| Stock awards | $1,399,928 |
| Option awards | $1,548,238 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $53,509 |
| Total | $3,104,857 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Tarsus Pharmaceuticals, Inc. DEF 14A filed April 28, 2025, accession 0001819790-25-000070, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Tarsus Pharmaceuticals, Inc. filed document, accession 0001819790-25-000070. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 27,278 | $1,510,383 | — |
| RSU | 3,350 | $185,490 | — |
| Option | 10,000 | — | $26.25 |
| Option | 5,000 | — | $33.14 |
| Option | 41,074 | — | $46.21 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Tarsus Pharmaceuticals, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Tarsus Pharmaceuticals’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Bobak Azamian | President, Chief Executive Officer and Board Chairman | $7,896,192 |
| Jeffrey Farrow | Chief Financial Officer and Chief Strategy Officer | $3,232,926 |
| Seshadri Neervannan | Chief Operating Officer | $3,194,689 |
| Aziz Mottiwala | Chief Commercial Officer | $3,138,862 |
| Elizabeth Yeu-Lin · this page | Chief Medical Officer | $3,104,857 |
Board service
Tarsus Pharmaceuticals board · FY2021–FY2023| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2023 | $59,125 | $61,506 | $59,574 | — | $180,205 |
| FY2022 | $46,000 | $26,180 | $64,256 | — | $136,436 |
| FY2021 | $240,000 | $0 | $382,612 | — | $622,612 |
Each year as the company reported it in Tarsus Pharmaceuticals's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: Tarsus Pharmaceuticals pays directors a $40,000 cash retainer. As stated in Tarsus Pharmaceuticals's FY2023 proxy.
Committees
Science and Technology (Chair)
The full Tarsus Pharmaceuticals compensation record
free company briefThis page is one person within Tarsus Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Tarsus Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Tarsus Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.